This article is more than 5 years old. Information may no longer be current.

FDA approves Roche’s cobas MPX test for use with cobas 6800/8800 systems

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved Roche’s cobas MPX test for use on the cobas 6800 and 8800 systems, according to a news release from the company.

The cobas MPX is a nucleic acid test for the detection of HIV, hepatitis B virus and hepatitis C virus in blood plasma and serum.

According to the release, it will allow donor screening laboratories in the United States to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood and plasma.

“This approval reinforces our strong presence in donor screening, and underscores our ability to provide proven, robust technology for the testing of donated blood and blood products,” Uwe Oberlaender, PhD, head of Roche Molecular Diagnostics, said in the release. “We will continue to partner with donor screening laboratories worldwide demonstrating our joint commitment to patient safety.”

Reference: Roche.

Disclosure: Oberlaender works for Roche.